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Abstract Interstrand crosslinks (ICLs) are a highly toxic
form of DNA damage. ICLs can interfere with vital bio-
logical processes requiring separation of the two DNA
strands, such as replication and transcription. If ICLs are
left unrepaired, it can lead to mutations, chromosome
breakage and mitotic catastrophe. The Fanconi anemia
(FA) pathway can repair this type of DNA lesion, ensuring
genomic stability. In this review, we will provide an
overview of the cellular response to ICLs. First, we will
discuss the origin of ICLs, comparing various endogenous
and exogenous sources. Second, we will describe FA pro-
teins as well as FA-related proteins involved in ICL repair,
and the post-translational modifications that regulate these
proteins. Finally, we will review the process of how ICLs
are repaired by both replication-dependent and replication-
independent mechanisms.
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Abbreviations
ATM Ataxia telangiectasia mutated
ATR ATM and Rad3-related
AML Acute myelogenous leukaemia
BCNU 1,3-Bis(2-chloroethyl)-1-nitrosourea









NER Nucleotide excision repair
NHEJ Non-homologous end joining
NO Nitric oxide
PTM Post-translational modification
ROS Reactive oxygen species
RPA Replication protein A
SUMO Small ubiquitin-like modifier
TLS Translesion synthesis
TMP Trimethylpsoralen
TNF-a Tumour necrosis factor-a
UAF1 USP1 associated factor 1
UHRF1 Ubiquitin-like containing PHD and RING finger
domains 1
USP1 Ubiquitin-specific peptidase 1
Introduction
Our genome is constantly exposed to damage caused by
both endogenous and exogenous sources. ICLs (inter-
strand crosslinks) are one of the most cytotoxic lesions
because the two Watson and Crick strands of DNA are
covalently bound together, causing an obstacle to repli-
cation and transcription. ICLs left unrepaired can lead to
mutations, chromosome breakage, chromosome misseg-
regation and mitotic catastrophe. To protect the genome
from this type of lesion, the cells count on a highly
complex repair pathway to detect the lesion, activate the
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cell cycle checkpoint and repair the ICLs. ICLs can be
generated by naturally occurring compounds, such as
psoralen and mitomycin C, as well as by chemically
synthesized crosslinking agents, such as cisplatin. ICL-
forming drugs are widely used as chemotherapeutic drugs
against cancer. Reactive aldehydes have been shown to be
one of the endogenous sources causing crosslinks. The
chemical structure of the resulting ICL depends on the
crosslinking agent implicated, and these different struc-
tures will lead to different cellular responses. The
response to ICLs triggers a complex DDR (DNA damage
response) including the Fanconi anemia (FA) pathway as
well as the ATR (ATM and Rad3-related)/Chk1 pathway.
Therefore, along the FA pathway, several signal trans-
duction events take place mediated by multiple
modifications including phosphorylation, ubiquitination
and SUMOylation (small ubiquitin-like modifier) events.
In order to fully repair the ICL, the FA pathway coordi-
nates different processes including translesion synthesis
(TLS), homologous recombination (HR) and nucleotide
excision repair (NER). Therefore, there is extensive
crosstalk between different DNA repair pathways during
ICL repair.
Origin of ICLs
ICLs are formed when the two strands of DNA are
covalently bound together through a linker molecule
commonly known as a crosslinking agent. The first
crosslinking agents to be identified were the nitrogen
mustards developed during the warfare of the early
twentieth century. A better application for these com-
pounds was found as chemotherapeutic agents, though
their mechanism of action was still unknown. Later
other compounds such as mitomycin C and cisplatin
joined them as chemotherapeutic agents and they were
all found to be crosslinking agents [1]. They can react
with DNA and give rise to different kinds of products
including DNA monoadducts, intrastrand crosslinks and
ICLs with variable efficiencies. They also differ in their
base specificity for ICL formation and the degree of
distortion in the DNA double helix they generate. Some
of these compounds, such as psoralens, which are pro-
duced by certain plants, may play an important role as
environmental sources of ICLs. However, the search for
endogenous sources of ICLs has rendered very inter-
esting results in the past few years, suggesting that
reactive aldehydes are one of the endogenous
crosslinking agents [2]. Some candidates include prod-
ucts derived from lipid peroxidation such as
malondialdehyde and crotonaldehyde, but also nitric
oxide has been proposed [3].
Nitrogen mustards
The most simple nitrogen mustard and the first to be used
as a chemotherapeutic agent is mechlorethamine (bis(2-
chloroethyl)methylamine) (Fig. 1a). Nitrogen mustards are
bifunctional alkylating agents, thus their chloroethyl moi-
eties can bind two bases on opposite strands of DNA. They
bind guanine N7 forming a monoadduct leading then to
binding a second guanine on the opposite strand in the
sequence GpNpC (Fig. 1a). Other nitrogen mustards, such
as melphalan and chlorambucil, substitute the methyl group
with aromatic groups and they can also bind adenine N3
[4]. The generated ICLs, which only account to up to 5 %
of the products, cause a distortion of the double helix with
an unwinding of 2–6 and a bend of around 10 per ICL
because of the shortening needed to accommodate the N7–
N7 bond [5, 6]. Recently, nitrogen mustards have been
engineered into activatable prodrugs. These new types of
aromatic nitrogen mustards generate ICLs only in the
presence of H2O2 providing a promising tool for the
treatment of tumours in a highly oxidative environment [7].
Mitomycin C
Mitomycin C (MMC) is a natural compound produced by
Streptomyces caespitosus. It is unable to bind DNA directly
but needs to be metabolically reduced beforehand. This
need for a reduction step for its activation makes MMC
especially fit as a chemotherapeutic agent since the tumour
micro-environment is generally hypoxic [8]. After reduc-
tion it specifically reacts with the N2 in guanine in the
sequence CpG and its complementary strand to form an
ICL (Fig. 1b) [8]. However, it can also form monoadducts
through the N7 of guanine [9]. ICLs constitute around
15 % of the products (the rest being 50 % monoadducts
and 35 % intrastrand crosslinks) [10]. MMC binds to the
N2 of guanines through the minor groove and it causes
only a minor distortion of the double helix [11].
Platinum compounds
Cisplatin [cis-diamminedichloroplatinum(II)] was first
described as a compound inhibiting bacteria growth in
1965 [12]. It reacts with purine residues to form intrastrand
and interstrand crosslinks. The intrastrand crosslinks are
formed at sequences GpG and ApG with a preference for
the former (65 and 25 % intrastrand crosslinks of total
adducts formed, respectively). ICLs are formed with a
lower frequency of around 5–8 %. ICLs are formed
specifically at GpC sites and bind N7 of guanine (Fig. 1c)
[13]. Both crystallographic and NMR structural models
have shown cisplatin ICLs to provoke a large distortion in
the DNA double helix. These ICLs induce the extrusion of
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two cytosines in the GC/CG sequence while the platinum
locates itself in the minor groove. The double helix suffers
an unwinding of 110 and a bent towards the minor groove
of 47 (Fig. 2b) [13, 14]. Other platinum compounds that
have also been studied and used as chemotherapeutic
agents include carboplatin and transplatin. Carboplatin
Fig. 1 Schematic
representation of the chemical
structure of the main
crosslinking agents and the
ICLs they form.
a Mechlorethamine (nitrogen
mustard), b mitomycin C,




(R = CH3)] and h nitric oxide.
Crosslinking agents are shown
in red
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differs from cisplatin in the chloride groups, which are
substituted with cyclobutyldicarboxylate. Carboplatin has
less reactivity than cisplatin, but it behaves similarly
regarding generation of ICLs and their frequency [15].
Transplatin, however, has been shown to induce only minor
distortion of the double helix when forming ICLs [16].
Moreover, by substituting the ammine groups in transplatin
with the planar bases quinoline or thiazole the frequency of
ICLs among the platinated products greatly increased to
around 30 % [17].
Psoralens
Psoralens belong to a family of molecules called furo-
coumarins. These compounds are produced by at least eight
families of plants including Apiaceae and Fabaceae [18].
The planar and hydrophobic nature of these molecules
allows them to easily penetrate the cell and intercalate the
DNA bases. However, they are unable to form ICLs until
irradiated with UVA (ultraviolet light), which induces
covalent bonds to thymines on the sequence TpA on
opposite strands (Fig. 1d). Psoralens are very effective
inducers of ICLs with around 40 % of adducts generated
being ICLs. However, a derivative of psoralen,
trimethylpsoralen (TMP) can form up to 90 % ICLs [19].
This is due to the incapacity to form intrastrand crosslinks
since psoralen must first intercalate the bases on opposing
strands of DNA before being photo-activated [20]. The
ICLs generated do not bend the DNA double helix and only
provoke a minor unwinding of around 25 (Fig. 2c) [21].
Nitrosoureas
Nitrosoureas such as BCNU (1,3-bis(2-chloroethyl)-1-ni-
trosourea) are able to react with guanine and cytosine after
metabolic activation. Their preferred site for binding is the
N7 of guanine, although the O6 of guanine can also be
attacked. Through this interaction BCNU can form intras-
trand crosslinks between adjacent guanines. ICLs are
formed in vitro when BCNU attacks O6 of guanine and N3
of cytosine on opposing strands though these adducts are
minor products [22]. Other ICLs formed includes the
binding of N1 of guanine with N3 of cytosine, which has
been observed in vivo in the treatment of brain cancers
(Fig. 1e). The structure of this crosslink has been studied
through NMR and was found to be well accommodated in
the double helix with very minor alterations (Fig. 2d) [23].
Diepoxybutane
1,2,3,4-Diepoxybutane (DEB) is a product of the bio-
transformation of 1,3-butadiene, a contaminating gas
produced in the plastic and rubber industry. DEB is a
bifunctional alkylating agent and reacts with DNA to
produce monoadducts, ICLs, single-strand breaks and also
DNA–protein crosslinks. However, in vivo ICLs are the
main product responsible for its cytotoxicity [24]. DEB
preferentially reacts with N7 and N1 in guanine, although
Fig. 2 Structures of various ICLs. a B-DNA and the ICLs formed by
b cisplatin, c psoralen, d BCNU and e acetaldehyde and crotonalde-
hyde viewed from the major groove (left) or the minor groove (right).
The crosslinked bases and the crosslinking agents are shown in red.
Structures taken from PDB, accession numbers: B-DNA (1-BNA)
[140], cisplatin (1A2E) [13], psoralen (204D) [21], BCNU (2MH6)
[23], acetaldehyde (2HMD) [29]
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ICLs are formed through N7–N7 at the sequence GpCpC
similarly to the nitrogen mustard mechlorethamine
(Fig. 1f) [25]. The bridge formed only contains four carbon
atoms, which has been hypothesized to produce a major
distortion on DNA. Through gel retardation experiments, it
has been shown to lead to a bending of around 34 towards
the major groove [26].
Endogenous crosslinking agents
Endogenous ICLs are especially difficult to study. Most
evidence of endogenous crosslinking agents comes from
in vitro studies or assessment of their mutagenicity [3].
Reactive aldehyde has been thought to be the major
endogenous crosslinking agent. One such aldehyde is
acetaldehyde. It was shown that acetaldehyde poses similar
cellular toxicity to FA-deficient cells compared to other
crosslinking agents suggesting that the FA pathway is
required for the repair of acetaldehyde-derived damage [2].
Acetaldehyde can be derived from the metabolism of
ethanol. It is able to react with guanine on DNA and, after a
reduction step, form N2-ethyl-20-deoxyguanosine.
Although this compound is the major adduct formed by
acetaldehyde, it cannot form ICLs. Two acetaldehyde
molecules can also react with guanine to form 1-N2-pro-
pano-20-deoxyguanosine, though the presence of basic
molecules such as histones is needed. This compound is
also generated by crotonaldehyde and it can exist in a
cyclic or open chain configuration. In the open chain form
the free aldehyde group can induce ICLs and DNA–protein
crosslinks [27]. These ICLs are generally found in a CpG
sequence but DNA–protein crosslinks constitute the main
type of modification generated by acetaldehyde (Fig. 1g)
[28]. These ICLs induced at CpG sequences by either
crotonaldehyde or acetaldehyde are located in the minor
groove and do not disturb the Watson–Crick pairing of the
bases implicated (Fig. 2e) [29].
Another endogenous source of ICL formation is lipid
peroxidation from oxidative stress, a process which is
promoted by a fat-rich diet in mice and potentially in
humans [30]. Lipid peroxidation leads to the production of
malondialdehyde (MDA). MDA can react with guanine,
adenine and cytosine though the main ICL produced is
between the guanines in the sequence CpG [31]. Other
products of lipid peroxidation include unsaturated aldehy-
des such as acrolein and crotonaldehyde. These can also
come from exogenous sources such as cigarette smoke and
automobile exhaust [32]. These aldehydes can react with
nitrogen bases either through the carbonyl group or the
double bond. The conjugate addition is followed by
cyclization onto the base to generate a monoadduct. The
ICL formed is present in CpG sequences as well and does
not disturb the structure of the double helix [32, 33].
Nitric oxide (NO) has also been shown to induce ICLs.
It generates ICLs between two guanine residues in the CpG
sequence, which are bound by a common N2 amine group
(Fig. 1h). This reaction might be favoured by the presence
of methylated cytosines [34].
The Fanconi anemia pathway
Our knowledge of an ICL repair pathway originates from
studies of an autosomal recessive disease called Fanconi
anemia (FA). FA is a rare genetic disorder with an inci-
dence of 1/200,000–1/400,000 in the general population
[35]. FA is characterized by developmental abnormalities
and early bone marrow failure, which leads to aplastic
anaemia. FA patients are susceptible to various types of
cancer, most often acute myelogenous leukaemia (AML).
The mechanism behind bone marrow failure in FA is
thought to be related to an excessive inflammatory
response and apoptosis mediated by tumour necrosis factor
a (TNFa), IFNc and reactive oxygen species (ROS) [36].
To date, 19 FA genes have been identified. Mutation in
these genes accounts for 95 % of the FA patients. Patients
are sensitive to ICL-forming agents, such as mitomycin C,
due to the cellular failure to repair ICLs. There is growing
evidence that the symptoms observed in FA patients are
also related to this defect in DNA repair. For instance, the
bone marrow failure characteristic of FA patients could be
originated from a defect in ICL repair in hematopoietic
stem cells exposed to endogenous crosslinking agents such
as formaldehyde [37]. This defective hematopoiesis leads
to cell death, injury and generates an inflammatory
response as previously observed, which further enhances
bone marrow failure through apoptosis, production of ROS
and inhibition of stem cell function [37, 38].
These 19 genes encode proteins, which together with
non-FA proteins as well as proteins from other DNA repair
pathways, including homologous recombination (HR),
nucleotide excision repair (NER) and translesion synthesis
(TLS), coordinate the detection and repair of ICLs as well
as activation of the cell cycle checkpoint (Table 1) [35,
39]. The 19 FA proteins can be divided into three groups
according to their functions in the pathway: the FA core
complex, the FANCD2/FANCI complex and the effector
proteins (Table 1).
First, eight FANC proteins (FANCA, FANCB, FANCC,
FANCE, FANCF, FANCG, FANCL and FANCM) and
three associated proteins (FAAP20, FAAP24 and
FAAP100) form the FA core complex. Among other pro-
teins that bind to some components of the core complex as
part of the core complex or forming independent com-
plexes, we find BLM (Bloom syndrome helicase), Topo
IIIa (topoisomerase IIIa), RPA (replication protein A) and
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MHF1/2 (histone fold heterodimer) [40–42]. BLM, Topo
IIIa and RPA interact with FANCA, FANCC, FANCE,
FANCF and FANCG in a complex named BRAFT. This
complex potentially plays a role in the FA pathway since
BLM deficiency leads to sensitivity to MMC [41, 42]. On
the other hand, MHF1/2 bind to FANCM and are recruited
to replication forks stalled by ICLs. MHF1/2 are also
needed for resistance to ICLs and promote FANCD2
monoubiquitination [40]. However, there is some debate
regarding whether FANCM can be considered an FA pro-
tein. The controversy arises from the fact that the first FA
patient identified with biallelic mutations in FANCM also
had alterations on FANCA [43] and also the observation
that individuals with homozygous loss of function of
FANCM did not display FA symptoms [44]. Despite these
observations, FANCM is usually included as an FA protein
and a component of the core complex. The FA core com-
plex together with FANCT (UBE2T) [45–47], a ubiquitin-
conjugating enzyme, is responsible for monoubiquitination
of the FANCD2/FANCI complex. FANCL, an E3 ligase, is
the catalytic enzyme carrying out the ubiquitination. While
mutations in some of the FA core complex members, such
as FANCA, FANCC and FANCG, account for 85 % of the
FA patients worldwide, the exact function of these mem-
bers remains elusive. FANCL and UBE2T are sufficient to
monoubiquitinate FANCD2/FANCI complex in vitro [48–
50] and, for instance in silkworm; there is an active FA
pathway in the absence of the FA core complex [51]. Loss
of different FA core complex members causes variable
degrees of sensitivity towards crosslinking agents. Some of
the FA core complex members are predicted to be entirely
helical and have no known conventional domains [52],
which makes it difficult to speculate on their molecular
functions. Recently, it was shown that a minimal sub-
complex containing FANCB, FANCL and FAAP100 is
required for robust FANCD2 monoubiquitination in DT40
cells and in vitro [53]. The rest of the FA core complex can
be divided into two subcomplexes, FANCA-FANCG-
FAAP20 and FANCC-FANCE-FANCF. Their presence
facilitates the activity and the recruitment of the whole FA
core complex onto DNA [54]. Nonetheless, this function
would be redundant with that of the translocase FANCM
[55]. The integrity of the FA core complex is also modu-
lated by post-translational modifications, e.g.
phosphorylation by ATR/Chk1 and ubiquitination.
Second, the FANCD2/FANCI complex resides at the
heart of the FA pathway. It is monoubiquitinated by the FA
core complex and is recruited to the ICLs. This is a critical
step for the ICL repair. If there is no monoubiquitination,
there will be no subsequent repair of the ICL. The function
of monoubiquitinated FANCD2/FANCI complex is not
fully understood. It is thought to orchestrate the recruitment
of the downstream effector proteins to the ICL. In addition
to monoubiquitination, the FANCD2/FANCI complex is
Table 1 FA proteins identified to date, their synonyms, size and function
FA protein Synonym Size (aa) Function
FANCA – 1455 FA core complex
FANCB – 859 FA core complex
FANCC – 558 FA core complex
FANCD1 BRCA2 3418 Homologous recombination
FANCD2 – 1451 Essential for the recruitment of downstream effector proteins
FANCE – 536 FA core complex
FANCF – 374 FA core complex
FANCG XRCC9 622 FA core complex
FANCI – 1328 Essential for the recruitment of downstream effector proteins
FANCJ BRIP1, BACH1 1249 Homologous recombination, helicase
FANCL – 380 FA core complex, E3 ubiquitin ligase
FANCM – 2048 FA core complex, DNA translocase
FANCN PALB2 1186 Homologous recombination, BRCA2 partner
FANCO RAD51C 376 Homologous recombination
FANCP SLX4 1834 Scaffolding protein for nucleases
FANCQ ERCC4, XPF 916 ERCC1 partner, nuclease
FANCR RAD51 340 Homologous recombination
FANCS BRCA1 1863 Homologous recombination, removes CMG
FANCT UBE2T 197 FANCL partner, E2 conjugating enzyme
Information based on [35, 39]. Although FANCM classification as an FA protein is controversial, it is still traditionally included (please see text
and [43, 44])
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also regulated by other post-translational modifications that
we will discuss extensively in a later section.
Third, FANCD1 (BRCA2), FANCJ (BRIP1), FANCN
(PALB2), FANCO (RAD51C), FANCP (SLX4), FANCQ
(XPF), FANCR (RAD51) and FANCS (BRCA1) are the
effector proteins that contribute to the ICL repair at later
stages (Table 1). BRCA1, BRCA2, BRIP1, PALB2,
RAD51 and RAD51C have been known for their roles in
homologous recombination, which plays an important part
in the FA pathway. Mutations in either BRCA1 or BRCA2
lead to higher risk of breast and ovarian cancer [56].
Recently, mutations in other FA genes such as BRIP1,
PALB2 and RAD51C have been associated with an inter-
mediate risk of breast cancer [57, 58]. FANCJ was shown
to interact with BLM, promoting its stability. This inter-
action is probably distinct from the BRAFT complex and
plays a potential role in the response to replication stress
[59, 60]. SLX4 is a nuclease scaffold protein interacting
with several nucleases including XPF/ERCC1, MUS81/
EME1 and SLX1. However, XPF is thought to be espe-
cially important in ICL unhooking.
In addition to the 19 FA proteins and 3 FA associated
proteins, there are other non-FA proteins that have been
shown to participate in the ICL repair. For example,
UHRF1 has been proposed to recognize ICLs in vivo and
in vitro [61, 62]. FAN1 (Fanconi-associated nuclease 1) has
been shown to be one of the nucleases important for the
ICL repair [63–67]. SNM1A is another nuclease that has
been demonstrated to participate in the ICL repair [68, 69].
Although the focus of this review is the response to
ICLs, alternative roles for the FA proteins are emerging in
recent years. There is growing evidence for the role of FA
proteins in replication fork protection and recovery after
stalling, whether caused by ICLs or other genomic stresses.
Monoubiquitinated FANCD2 has been shown to recruit the
nuclease FAN1, as well as other FA mediators such as
BLM, FANCJ and BRCA2, independently of the core
complex, to promote fork recovery and genomic stability
[70–72]. Another source of genomic instability are the
ultra-fine DNA bridges or UFBs that interlink chromo-
somes during mitosis. These UFBs are thought to arise
from common fragile loci that associate with FANCD2 and
FANCI even through mitosis when BLM is also found at
the UFBs. These proteins are thought to contribute to the
resolution of the UFBs ensuring a correct chromosomal
segregation, but the exact mechanism remains unclear [73,
74]. FA proteins have also been associated with the pro-
cessing of transcription associated DNA: RNA hybrids,
also known as R-loops, and the stabilization of replication
forks stalled by these structures [75]. Mainly, FANCM was
found to resolve R-loops through its translocase activity
and, surprisingly, aldehydes were observed to induce
R-loops, adding another by-product of their activity to the
different adducts already discussed [75].
Post-translational modifications of the FA proteins
Repair of an ICL is a highly complex process involving the
FA pathway as well as other repair pathways. Post-trans-
lational modifications (PTMs) play an essential role in the
regulation of this process. Depending on the type of
modification, PTMs can cause protein conformation or
surface charge changes or could establish new protein–
protein interactions that trigger signal transduction or
degradation. There are many PTM events in the FA path-
way identified over the past decade (Table 2). One of the
keystones is the monoubiquitination of FANCD2 that is
required for its localization at the ICLs. However, this
modification is preceded by several phosphorylation events
on different proteins and mainly mediated through ATR/
ATM (ataxia telangiectasia mutated) kinases and down-
stream target kinases Chk1 and Chk2. Additionally,
recently light has been shed on the role of SUMOylation in
the FA pathway [76, 77] as well as on the termination
events that shut off the pathway in a timely manner once
the repair has been completed (Fig. 3). It should be noted
that many of the PTMs identified so far for the effector
proteins implicated in HR have been linked to DSB (double
strand break) repair and not to ICLs. However, these
mechanisms could play similar roles in response to
crosslinking agents as well.
Phosphorylation
The FA pathway relies on several phosphorylation events
of different proteins in the core complex and the FANCD2/
FANCI heterodimer leading to the monoubiquitination of
FANCD2 (Fig. 3). Two kinases are at the centre of the
DNA damage response: ATM and ATR that phosphorylate
several proteins involved in DNA repair, including other
kinases such as Chk1 and Chk2. Although ATM phos-
phorylates FANCD2 on its S222 in vitro and in human
cells, this event is not necessary for its monoubiquitination
or ICL repair. Rather, the phosphorylation event regulates
the S-phase checkpoint, which inhibits DNA replication
after IR treatment (Table 2) [78]. However, ATR was
found to be required for FANCD2 monoubiquitination
upon MMC or IR treatment. The absence of ATR also
abrogated FANCD2 foci formation and led to chromoso-
mal abnormalities in cells derived from a patient with
Seckel syndrome [79]. Two sites were identified on
FANCD2, T691 and S717, which can be phosphorylated by
ATR and ATM both in vitro and in human cells, but could
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not fully account for the phenotype observed in the absence
of ATR. These two sites were not essential for FANCD2
monoubiquitination, though if mutated led to an increase in
sensitivity to MMC pointing to a role in ICL repair and also
affected the intra-S-phase checkpoint (Table 2) [80]. Other
components of the ATR pathway can promote the efficient
monoubiquitination of FANCD2 and ICL resistance,
mainly RAD9 and RAD17 [81]. It was also found that
Chk1 and its partner CLASPIN are necessary for efficient
FANCD2 monoubiquitination in response to DNA damage
in human cells, but whether this happens downstream or
independently of the ATR/RAD17/RAD9 pathway remains
unknown [81]. The identification of a new phosphorylation
site on FANCD2, S331, shed more light on this problem.
The lack of phosphorylation on this site also led to sensi-
tivity to MMC and disrupted the interaction with BRCA2
(FANCD1) in human cells. This site is phosphorylated by
Chk1 both in vitro and in vivo, which could be a potential
explanation for the role of the ATR pathway through Chk1
in promoting FANCD2 monoubiquitination and ICL repair
(Table 2) [82].
Phosphorylation of FANCI was also found to be
important for FANCD2 monoubiquitination and foci for-
mation. Several conserved sites (at least six) on FANCI
with the motif Ser/Thr-Gln predicted to be phosphorylated
by ATM or ATR were responsible for the observations in
chicken DT40 cells. This phosphorylation event could be a
switch for the monoubiquitination and recruitment of
FANCD2 onto DNA. However, the monoubiquitination of
FANCI was dispensable for monoubiquitination and
recruitment of FANCD2 to ICLs [83]. Further evidence for
the role of ATR in the response to ICLs came from
Table 2 Summary of the main PTMs of FA proteins and their function in the response and repair of ICLs
FA
protein
Site Post-translational modification Function
FANCA S1449 Phosphorylated by ATR Promotes FANCD2 monoubiquitination specifically after DNA
damage [87]
– SUMO-mediated by UBC9 and
polyubiquitinated by RNF4
Proteasome degradation, pathway termination [77]
FANCE T346 and S374 Phosphorylated by Chk1 Proteasome degradation, pathway termination [88]
FANCG K182, K258 and K347 Polyubiquitinated Interaction with BRCA1 and HR [110]
S383 and S387 Phosphorylated by Cdc2 Dissociation from chromatin in mitosis, pathway termination [79]
FANCM S1045 Phosphorylated by ATR Enhances chromatin localization after DNA damage and S phase [89,
90]
– Phosphorylated by Plk1 Degradation of FANCM in M phase and core complex release [92]
FANCD2 S222 Phosphorylated by ATM Regulation of intra-S-phase checkpoint [78]
S331 Phosphorylated by Chk1 Interaction with BRCA2, MMC sensitivity [82]
K561 Monoubiquitinated by FANCL Enhances chromatin recruitment, interaction with effector proteins
[100, 101]
T691 and S717 Phosphorylated by ATR or ATM Regulation of intra-S-phase checkpoint, MMC sensitivity [80]
– SUMOylated by PIAS1/4 and
polyubiquitinated by RNF4
Chromatin dissociation [76]
FANCI S556, S559, S565,
S596 and S617
Phosphorylated by ATR Required for FANCD2 monoubiquitination [83]
K563 Monoubiquitinated by FANCL Maintenance of FANCD2 monoubiquitination [48, 105]
– SUMOylated by PIAS1/4 and
polyubiquitinated by RNF4
Chromatin dissociation [76]
FANCJ S990 Phosphorylated probably by Cdks Regulation of the DNA damage checkpoint [99]
PALB2 K25, K30 Ubiquitinated by KEAP1-CUL3-
RBX1
Inhibition of HR during G1 phase [109]
BRCA1 S1497, S1189 and
S1191
Phosphorylated by Cdk1 BRCA1 foci formation and DNA damage checkpoint signalling [96]
S1164 (others) Phosphorylated by Plk1 BRCA1 foci formation after DSB [95]
S988 Phosphorylated by Chk2 BRCA1 degradation and dissociation from DSB [97, 98]
K32 and K1690
(others)
SUMOylated BRCA1 accumulation on DSB and enhanced ubiquitin
ligase activity [111, 112]
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experiments with chicken DT40 cells lacking expression of
ATRIP, an ATR interacting partner needed for its activa-
tion. In this case, there was also a reduction in FANCD2
and FANCI monoubiquitination as well as in FANCI
phosphorylation after MMC treatment. FANCI was phos-
phorylated by ATR in vitro and the reaction was enhanced
by the presence of FANCD2 and the core complex [84].
Several components of the core complex also undergo
phosphorylation although with different effects on the FA
pathway. FANCG, for example, is phosphorylated during
mitosis in human cells and this was related to the disso-
ciation of the core complex from chromatin once the repair
is completed [85]. Later, two residues were identified as
responsible for this event, S383 and S387. S387 was
phosphorylated (in vitro and in human cells) by Cdc2,
which associates with the core complex in mitosis
(Table 2) [86].
A more critical role in the FA pathway and ICL repair
was found for the phosphorylation of FANCA on S1449.
Phosphorylation on this site occurred specifically after
DNA damage and not during unperturbed S-phase, unlike
FANCD2 monoubiquitination and FANCG phosphoryla-
tion, which happen also during S-phase. Lack of
phosphorylation on this site reduced FANCD2 monoubiq-
uitination and led to partial sensitivity to MMC. ATR
phosphorylated S1449 in vitro and was necessary for the
phosphorylation in human cells (Table 2) [87].
Another component of the core complex, FANCE, is
also phosphorylated after DNA damage. Chk1 phospho-
rylates FANCE on T346 and S374 both in vitro and in
human cell lines (Table 2) [88]. However, this event is
independent of FANCD2 phosphorylation and foci for-
mation. The fact that FANCE phosphorylation was
necessary to fully complement FANCE-deficient cells
suggests it is still an important event in the FA pathway and
ICL repair. FANCE phosphorylation promotes its degra-
dation, thus it was proposed to play a role in the
termination of the pathway to complete the repair [88].
Recruitment of the core complex to DNA is usually
attributed to FANCM and its phosphorylation could play a
critical role in the process. Studies in cell-free Xenopus egg
extracts showed that FANCM is hyperphosphorylated
during S-phase as well as after DNA damage and this
enhances its chromatin localization. ATR and ATM regu-
late this process. Surprisingly, these events were shown to
be favoured by the presence of FANCD2, pointing to a
positive feedback-loop taking place (Table 2) [89, 90].
Similar results were obtained in human cell lines where
S1045 on FANCM was found to be a target for ATR and
necessary for its localization on ICLs as well as the acti-
vation of the G2-M checkpoint [90]. There is evidence for a
role of ATR physically mediating the recruitment of
FANCM to the damaged DNA during replication in human
cells. ATR/ATRIP is recruited to stalled replication forks
through interaction with RPA, which then interacts with
HCLK2. HCLK2 can then recruit the heterodimer formed
by FANCM and FAAP24, providing a potential mechanism
for the recruitment of the core complex in an ATR-
checkpoint signalling dependent manner [91]. On the other
hand, when the cell enters M-phase FANCM is hyper-
phosphorylated and degraded, thus promoting the
dissociation of the core complex from chromatin. This
Fig. 3 Diagram of the main posttranslational modification events
involved in the activation of response to ICLs. Once the ICL is
detected it triggers the ATR/Chk1 pathway leading to the phospho-
rylation of several components of the FA core complex. ATR and
potentially other kinases phosphorylate FANCI and FANCD2 (1)
priming the complex for its monoubiquitination. These phosphory-
lation events lead then to the monoubiquitination of the FANCD2/
FANCI complex by FANCL/UBE2T (2), which promotes its
recruitment onto chromatin and the action of the effector proteins.
On the other hand, the dosage of the FANCD2/FANCI complex on
chromatin can be regulated through SUMOylation-dependent polyu-
biquitination mediated by PIAS1/4, UBC9 and RNF4 (3, 4). Finally,
these events can be reversed by the action of a hypothetical
deubiquitinase (5), SENP6 (6), the deubiquitinating enzyme USP1/
UAF1 complex (7) as well as putative phosphatases (8) still
unidentified
Cellular response to DNA interstrand crosslinks: the Fanconi anemia pathway 3105
123
phosphorylation-dependent degradation was mediated by
b-TRCP and Plk1 (Polo-like kinase 1) in human cells [92].
Among the effector proteins, phosphorylation of those
implicated in HR is well established in response to IR and
therefore, in DSB repair. However, given that these mod-
ifications may also play a role in ICL repair we will discuss
some of them (Table 2). Phosphorylation of BRCA1 by
ATM was one of the first modifications found that played a
role in DSB repair [93]. Later, BRCA1, BRCA2 and
PALB2 together with other proteins already discussed
(FANCD2, FANCI) were identified as substrates for ATR
and ATM in response to DSBs as part of a complex protein
network [94]. BRCA1 is a key regulator of HR and several
kinases have been linked to its function and regulation.
Cdk1 and Plk1 phosphorylate BRCA1, probably in a
sequential way, promoting BRCA1 foci formation follow-
ing DSB in human cells [95, 96]. On the other hand, Chk2
phosphorylation of BRCA1 leads to its degradation and
dissociation form DSB in human cells. This allows the
nuclease MRE11 to be recruited so that end resection and
HR can proceed during S/G2 phase [97, 98]. The BRCT
domain of BRCA1 has been characterized as a phospho-
protein-binding domain and one of its binding partners is
FANCJ. Phosphorylation of FANCJ on S990 during S/G2
phase was shown to be essential for the interaction with
BRCA1 in human cells, controlling the cell cycle as part of
the DNA damage checkpoint [99].
Ubiquitination
A central step in the FA pathway is the monoubiquitination
of FANCD2 on Lys561 (human) that ensures its recruit-
ment to damaged DNA as well as its interaction with other
effector proteins such as BRCA1 (FANCS) (Table 2)
[100]. The E3 ubiquitin ligase catalysing this step was
found to be FANCL, a member of the core complex [101].
FANCL works together with the E2 conjugating enzyme
UBE2T (FANCT) to monoubiquitinate FANCD2 (Fig. 3).
UBE2T can also monoubiquitinate itself on K91 decreas-
ing its own activity as a potential regulatory mechanism
[102]. FANCL contains three domains: an N-terminal E2-
like fold (ELF) domain, a central double RWD domain and
a C-terminal RING domain. The RING domain binds to
UBE2T while the RWD domain binds to FANCD2 [103].
The ELF domain interacts with ubiquitin and is important
for the monoubiquitination of FANCD2 upon DNA dam-
age in chicken DT40 cells (though not in vitro) [104]. The
binding partner of FANCD2, FANCI, is also monoubiq-
uitinated in vivo, and is required for the
monoubiquitination of FANCD2 and restricts it to K561
[48, 105]. Furthermore, the presence of DNA greatly
enhances FANCD2 monoubiquitination but only in the
presence of FANCI in vitro, suggesting that the
monoubiquitination in vivo occurs on the DNA and when
FANCD2 and FANCI are in complex [49]. Finally,
FANCD2 is deubiquitinated by the USP1/UAF1 deubiq-
uitinating enzyme complex (Fig. 3) [106, 107].
Ubiquitination also plays a critical role in an alternative
model for the recruitment of the core complex. In this study
in human cells, RNF8 together with UBC13 promotes K63
polyubiquitination of histone H2A in response to DNA
damage and this polyubiquitin is recognized by FAAP20
bringing the core complex onto damaged DNA [108]. In
fact, RNF8 and FAAP20 were needed for efficient
FANCD2 monoubiquitination after MMC treatment and,
thus, for efficient ICL repair [108].
Ubiquitination has also been linked to the regulation of
effector proteins implicated in HR. PALB2 and BRCA1
interaction is required for HR during G1 phase. However,
PALB2 ubiquitination on its BRCA1 binding motif abro-
gates this interaction in 293T cells after IR (Table 2) [109].
Recently, the polyubiquitination of FANCG via K63
linkage has been found to mediate its interaction with
BRCA1 and play an important role in HR in ICL repair in
human cells [110]. Three potential target lysines for this
process were identified: K182, K258 and K347 (Table 2)
[110].
SUMOylation
Alongside the ubiquitination and phosphorylation events in
the FA pathway, several SUMOylation events have started
to be discovered in recent years. SUMOylation, therefore,
provides a further step of regulation of the already complex
cellular response to ICLs. As discussed before, FANCD2
and FANCI form a heterodimer that is both phosphorylated
and monoubiquitinated in order to appear on ICLs. A
subpopulation of FANCD2 and FANCI is also SUMOy-
lated in response to DNA damage. This SUMOylation is
performed by PIAS1/4 and UBC9 on the chromatin-bound
complex in human cell lines while it can be reversed by
SENP6 (Table 2) [76]. SUMOylated FANCD2/FANCI can
then bind RNF4 which polyubiquitinates the complex. This
polyubiquitinated complex then interacts with DVC1-p97
promoting its dissociation from chromatin (Fig. 3).
Therefore, this mechanism could control the dosage of
FANCD2/FANCI on the chromatin avoiding further
recruitment of nucleases to DNA and allowing for a
dynamic regulation of the pathway [76].
The study of a patient-derived FANCA mutation iden-
tified in the clinic has led to the discovery of a regulatory
mechanism through its SUMOylation-dependent polyu-
biquitination and degradation. This mutant form, FANCA-
I939S, failed to interact with FAAP20 and this led to its
SUMOylation by UBC9, increased polyubiquitination by
RNF4 and degradation via the proteasome (Table 2) [77].
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SUMOylation of BRCA1 by SUMO2/3 in response to
DSB has also been described both in vitro and in vivo in
mammalian cell lines [111, 112]. SUMOylation of BRCA1
at its RING and BRCT domains (K32 and K1690,
respectively) promotes the binding to other proteins
through SIMs (SUMO-interacting motifs), which in this
case would enhance accumulation on DNA and its ubiq-
uitin ligase activity [111, 112].
These examples could illustrate a more general mecha-
nism for SUMO signalling as already shown for DNA
double-strand break repair [113]. In this case, SUMO
modifications target several proteins in a group, such as the
core complex or the FANCD2/FANCI complex, thereby
promoting interactions through the SUMO-SIMs of the
components synergistically. At a later stage, this leads to
their polyubiquitination and degradation to ensure the ter-
mination of the repair and the progression of the cell cycle.
Recognition of the ICL
When ICLs occur in the cells, the UHRF1 protein is
recruited to sites of damage within seconds [61, 62] (Fig. 4,
step 1). UHRF1 recognizes ICLs through its SET and
RING finger associated (SRA) domain, which was previ-
ously known for its role in recognizing hemi-methylated
DNA and subsequent recruitment of DNMT1 to maintain
the methylation signature in mammalian cells [114–117].
The affinities of UHRF1 to hemi-methylated DNA and to
ICLs are similar, suggesting that UHRF1 could interact
with hemi-methylated DNA and ICLs through related
mechanisms. The recruitment of UHRF1 precedes and is
required for proper recruitment of FANCD2 to ICLs [61].
There is about 10 min time lag between UHRF1 and
FANCD2 recruitment to ICLs, which leaves room for
speculation that recruitment of other proteins or PTM
events might take place within this time frame. The exact
mechanism of how UHRF1 facilitates FANCD2 recruit-
ment or subsequent repair is still unclear, but might entail a
direct protein–protein interaction. It has also been sug-
gested that UHRF1 plays a role as a nuclease scaffold [62].
It is possible that the rapid recruitment of UHRF1 to the
ICLs primes the lesion for FA mediated accurate repair
later. Due to the diversity in structures of different ICLs
(Figs. 1, 2), it is possible that other ICL sensor proteins
exist in addition to UHRF1.
Canonical FA pathway coordinated ICL repair
It is generally believed that the FA pathway is active solely
in the S-phase and that the majority of ICLs are repaired in
a replication-dependent manner [118]. The repair of ICLs
requires coordination of several different DNA damage
repair pathways including NER, HR and TLS. It is thought
that the FANCD2/FANCI complex and the FA pathway is
at the centre orchestrating the order of various events to
resolve ICLs. Notably, it has been suggested that the FA
pathway antagonizes the NHEJ pathway [119–121], which
further emphasizes the importance of the FANCD2/FANCI
complex.
There are several models of the replication-coupled ICL
repair (Fig. 4). One possibility is that the fork undergoes
FANCM/MHF complex-mediated traverse of the ICL,
which is independent of the rest of the FA core complex
and FANCD2/FANCI complex [19] (Fig. 4, step 3). The
ICL traverse mechanism leaves behind the ICL, which has
an X-shaped structure similar to that of a stalled replication
fork. Due to the structure similarity, it has been implied
that it is subsequently repaired by the canonical ICL repair
mechanism.
Alternatively, when the replication fork collides with an
ICL, the CMG helicase first undergoes BRCA1 (FANCS)-
mediated unloading to allow the replicative polymerase e
to approach the ICL [122] (Fig. 4, step 5). The FANCD2/
FANCI complex is then recruited to the arrested fork
(Fig. 4, step 8), and monoubiquitinated by the FA core
complex [123] (Fig. 4, step 9). Whether the FANCD2/
FANCI complex is monoubiquitinated prior to recruitment,
or on chromatin, remains elusive (Fig. 4, step 7). The
K561R mutation of FANCD2 abrogates monoubiquitina-
tion and chromatin recruitment of FANCD2/FANCI
complex and sensitizes cells to crosslinking agents, [78,
124]. However, it is also possible that the monoubiquiti-
nation of FANCD2/FANCI complex is critical for its
retention at the ICL rather than the actual recruitment to the
ICL. Recent studies show that DNA stimulates the ubiq-
uitination of FANCD2/FANCI in vitro [49, 53, 125], which
implies that the interaction between the FANCD2/FANCI
complex and DNA may contribute to the regulation of its
monoubiquitination in vivo. The monoubiquitinated
FANCD2/FANCI complex recruits the XPF/ERCC1/SLX4
nuclease complex (Fig. 4, step 10) and the nucleases carry
out incisions at the ICL to unhook the crosslinked bases
[126–128]. The TLS polymerase Rev1–polf complex,
which can accommodate bulky DNA substrates, is subse-
quently recruited to the lesion to carry out insertion through
the unhooked ICL base pair (Fig. 4, step 12) [129]. Inter-
estingly, the FA core complex, but not the FANCD2/
FANCI complex, regulates recruitment of the Rev1–polf
complex [129]. The double-strand break generated by the
incision is resected by CtIP, which is recruited through
monoubiquitinated FANCD2 [130, 131], potentially toge-
ther with the MRN (MRE11-RAD50-NBS1) complex and
the nucleases EXO1 and DNA2. MRE11 has been shown
to interact with FANCJ, which potentially regulates its
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nuclease activity ensuring a correct end resection [132].
The DSB is, then, repaired by RAD51-mediated homolo-
gous recombination (Fig. 4, step 13) [133]. To complete
the repair of the ICL, the unhooked lesion needs to be
removed. It is generally thought that the NER pathway is
involved in the process (Fig. 4, step 15) [134, 135], though
the precise molecular mechanism remains elusive.
Alternative ICL repair pathway in G1
In addition to replication-coupled ICL repair, there is
increasing evidence for the existence of a replication-in-
dependent ICL repair mechanism. Although it has been
understudied, replication-independent ICL repair may play
a significant role in maintaining genome integrity in non-
cycling cells, e.g. neurons.
It has been shown that ICLs can be removed via the
NER pathway independently of replication [136–139].
NER proteins XPA, XPB, XPC and XPF are recruited to
psoralen/UVA induced ICLs and monoadducts within
minutes in the G1-phase of the cell cycle and this ICL
repair process is dependent on Polf and XPC [137, 138]. It
has also been shown that transcription coupled-NER (TC-
NER) is crucial for cisplatin-induced ICL repair [136, 139].
The detailed molecular mechanism of the replication-
independent ICL repair is still unclear. It is likely that in
the absence of arrested replication forks, the activation of
ICL repair relies on the proteins recognizing the distorted
DNA helix and/or the collision of the RNA transcription
machinery with an ICL. There are some contradictions in
the literature whether XPC is involved in the replication-
independent repair. The ICL-forming agents used in the
studies mentioned above differ from study to study, but are
still generally considered to pose similar replicative stress.
As discussed previously, these crosslinking agents create
structurally distinct ICLs, which could give rise to the
discrepancies observed.
Conclusion
Genetic and biochemical studies carried out by various
groups have advanced our understanding of ICL repair for
the past decade and beyond. 19 FA genes have been
identified and the corresponding proteins cooperate with
other proteins in HR, NHEJ, TLS and NER to resolve
ICLs. However, the more we have learnt, the more ques-
tions have arisen. For instance, UHRF1 has been shown to
sense ICLs induced by TMP/UVA in vivo. Besides, the
recruitment of UHRF1 to ICLs precedes and is required for
FANCD2 recruitment. Nonetheless, it is unclear how
UHRF1 contributes to the regulation of FANCD2, whether
directly or indirectly. Also, it has been well accepted that
the FANCD2/FANCI complex is monoubiquitinated prior
to its recruitment to ICLs. However, in the crystal structure
of the mouse FANCD2/FANCI complex, the ubiquitination
sites are embedded in the heterodimer interface. Recent
studies show that DNA stimulates the in vitro ubiquitina-
tion of the FANCD2/FANCI complex [49, 125], suggesting
that the interaction of the complex with DNA might be
required for, and thus precede, the ubiquitination event.
Such a mechanism could potentially involve a conforma-
tional change of the complex upon interaction with DNA,
in turn stimulating the ubiquitination, perhaps by allowing
the FA core complex access to the target lysines. One of
the common features of the FA proteins is the lack of
predictable domains, which otherwise could help towards
deciphering their exact functions. More structural studies
of proteins involved in ICL repair will be required to
achieve a full mechanistic understanding of this compli-
cated process. Finally, different crosslinking agents have
been thought to cause similar cellular toxicities and the
resulting ICLs would be sensed and resolved through the
same pathway. However, the nature of the ICLs induced by
different crosslinking agents is different. We may need to
re-think how we depict the pathways resolving ICLs, which
could be more complicated than we currently imagine. For
instance, ICLs induced by MMC and TMP/UVA cause a
minor distortion of the DNA double helix and can be
recognized by XPC and UHRF1, respectively [61, 137]. On
the other hand, ICLs caused by cisplatin cause a major
distortion of DNA, which may require other sensor proteins
or collision of the replication and transcription machineries
with the ICL to activate the signal cascade. Thus, different
ICLs may lead to activation of different, though related,
repair mechanisms.
bFig. 4 Schematic of ICL repair. 1 UHRF1 is recruited to ICLs
through its SRA domain shortly after ICLs are formed in the cell. 2
Single replication fork arrives at the ICL. 3 FANCM/MHF complex
mediates the traverse of the replication machinery through the ICL,
which allows the replication fork to proceed, and leaves the ICL for
later repair. 4, 5 Alternatively, BRCA1 (FANCS) facilitates the
unloading of the CMG helicase complex when the second replication
fork arrives at the ICL. 6 The replicative polymerase proceeds to the
-1 position of the ICL, which leaves an X-shaped structure similar to
the traverse mechanism. 7 ATR phosphorylates FANCD2/FANCI
complex at multiple sites and FA core complex monoubiquitinates
FANCD2/FANCI complex at K561 and K523, respectively. 8
FANCD2/FANCI is recruited to the ICL at the replication fork. 9,
10 Ubiquitinated FANCD2/FANCI complex recruits SLX4/XPF to
ICL to unhook the ICL. 11 CtIP and the MRN complex resect the
double-strand break ends generated by the incision in the previous
step, and BRCA2 facilitates Rad51 filament formation on the ssDNA
generated by the resection. 12 Polf polymerizes new strand of DNA
through the unhooked ICL. 13 Rad51 facilitates the strand invasion,
which allows extension of the other strand. 14 SLX4 and nucleases
resolve the double Holliday junction. 15 NER repair proteins remove
the damaged nucleotide
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